New drug combined with standard medicines for AML patients not fit for intensive chemo
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (CLN-049) combined with two standard AML medicines (azacitidine and venetoclax) for people who are newly diagnosed with AML and cannot have intensive chemotherapy. It aims to see if this combination is safe and effective for those who are not fit for the usual strong treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must have recently been diagnosed with AML and not yet received any treatment for it
- You must not be able to receive standard intensive chemotherapy because of health reasons
- Your white blood cell count must be reasonably controlled (below a certain level) at the start of treatment
- You must be in generally good physical condition (able to take care of yourself, up and about most of the day)
- You must have adequate kidney and liver function (checked by blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of venetoclax and azacitidine in people with acute myeloid leukemia (AML) who have a high percentage of blast cells (at least 20%) in their bone marrow or blood. It aims to see if this treatment approach can improve outcomes for patients regardless of previous treatments or transplant history.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent (HMA), as the first treatment for adults with a type of leukemia called AML. The goal is to see if this combination works well and is safe for patients who have not had prior chemotherapy.
This trial tests a new combination of two drugs—venetoclax and azacitidine—for people with acute myeloid leukemia (AML) who can't have standard intensive chemo. The goal is to see if adding a boosting medicine (cobicistat) makes the treatment work better and is safe for you.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.